Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 140 No. 2930 (2010)

Skin cancers in renal transplant recipients: a description of the renal transplant cohort in Bern

  • B Keller
  • LR Braathen
  • HP Marti
  • RE Hunger
DOI
https://doi.org/10.4414/smw.2010.13036
Cite this as:
Swiss Med Wkly. 2010;140:w13036
Published
19.07.2010

Abstract

Background/aims: Skin tumours, in particular squamous-cell carcinomas (SCC), are the most common malignant conditions developing in transplant recipients. The aim of this study is to investigate the frequency and type of skin cancer in patients receiving immunosuppressive therapy after organ transplantation.

Methods: Multivariate logistic regression analysis was performed on data of 243 renal transplant patients who attended the dermatology outpatient clinic for the first time after transplantation in the period January 2002–October 2005.

Results: We found an increased risk of actinic keratosis (AK) and SCC in renal transplant recipients with a basal cell carcinoma (BCC) / SCC ratio of 1:7. Older patients had AK more frequently (odds ratio [OR] 1.11, 95% confidence interval [CI] 1.06–1.15; p <0.0001) and SCC (OR 1.14, CI 1.07–1.22; p <0.0001) than younger patients. Men had AK (OR 0.19, CI 0.08–0.45; p = 0.0002) and SCC (OR 0.25, CI 0.07–0.89; p = 0.0332) more frequently than women. The duration of immunosuppressive therapy correlated significantly with the numbers of AKs (OR 1.15, CI 1.08–1.24; p <0.0001) and SCCs (OR 1.16, CI 1.05–1.28; p = 0.0025), and patients with fair skin had more AKs (OR 0.31, CI 0.14–1.24; p <0.0001) and SCCs (OR 0.11, CI 0.02–0.52; p = 0.0054) than darker skinned patients. We could not identify any specific immunosuppressive drug as a distinct risk factor for AK or non-melanoma skin cancer (NMSC).

Conclusion: Skin cancers are increased in the renal transplant population. Main risk factors for skin cancers are fair skin type and long duration of immunosuppressive therapy. A follow-up programme is necessary for early detection of skin cancer and precancerous conditions. Preventive strategies should include specialist dermatological monitoring and self-examination.

References

  1. Stockfleth E, Ulrich C, Meyer T. Skin diseases following organ transplantation – risk factors and new therapeutic procedures. Transplant Proc. 2001;33:1848–53.
  2. Berg D, Outley C. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47:1–17.
  3. Knoll G. Trends in kidney transplantation over the past decade. Drugs. 2008;68(Suppl 1):3–10.
  4. Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve years’ experience with national sharing of HLA-matched cadaveric kidney for transplantation. N Engl J Med. 2000;343:1078–84.
  5. Bouwes-Bavinck JN, Hardie DR, Green A, Cutmore S, Mac-Naught A, O’Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation. 1996;61:715–21.
  6. Euvrard S, Chardonnet Y, Pouteil-Noble C, et al. Association of skin malignancies with virous and multiple carcinogenic and non carcinogenic human papillomaviruses in renal transplant recipients. Cancer. 1993;72:2198–206.
  7. Casabonne D, Lally A, Mitchell L, Michael KM, Waterboer T, Pawlita M, et al. A case-control study of cutaneous squamous cell carcinoma among Caucasian organ transplant recipients: the role of antibodies against human papillomavirus and other risk factors. Int J Cancer. 2009;125(8):1935–45.
  8. Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy in the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation. 1987;44:429–34.
  9. Servilla KS, Burnham DK, Daynes RA. Ability of cyclosporine to promote the growth of transplanted ultraviolet radiation-induced tumors in mice. Transplantation. 1987;44:291–5.
  10. Boyle J, MacKie RM, Briggs JD, Junor BJ, Aitchison TC. Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet. 1984;1:702–5.
  11. O’Donovan P, Perett CM, Xlaohong Z, Karran P, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309:1871–74.
  12. Sheil AG. Development of malignancy following renal transplantation in Australia and New Zealand. Transplant Proc. 1992;24:1275–9.
  13. Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol. 1999;40:27–34.
  14. Moloney FJ, Comber H, O’Lorcain P, O’Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol. 2006;154(3):498–504.
  15. Hartevelt MM, Bacinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation. 1990;49:506–9.
  16. Naldi L, Fortina AB, Lovati S, Barba A, Gootti E, Tessari G, et al. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. Transplantation. 2000;70:1479–84.
  17. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet. 1995;346:403–6.
  18. Marubayashi S, Tashiro H, Watanabe H, Fubada Y, Hayamizu K, Ohdan H, et al. Study on eight patients with malignant tumors after renal transplantation. Hiroshima J Med Sci. 2000;49:117–20.
  19. Kishikawa H, Ichikawa Y, Yazawa K, Hanafusa T, Fukunishi T, Ebisui C, et al. Malignant neoplasm in kidney transplantation. Int J Urol. 1998;5:521–5.
  20. Jensen P, Hansen S, Moller B, Leivestad T, Pfefer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177–86.
  21. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000;23:101–13.
  22. Penn I. Cancers in renal transplant recipients: Adv Ren Replace Ther. 2000;7:147–56.
  23. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism: Nature. 1999;397:530–4.
  24. Bulliard JL, Panizzon RG, Levi F. Epidemiology of epithelial skin cancers. Rev Med Suisse. 2009;5(200):882,884–8.
  25. Hardie I, Strong R, Hartley L, Woodruff P, Clunie C. Skin cancer in caucasian renal allograft recipients living in a subtropical climate. Surgery. 1980;87:177.
  26. Gupta A, Cardella C, Haberman H. Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol. 1986;122:1288.
  27. Webb MC, Comptom F, Andrews PA, Koffman CG. Skin tumours posttransplantation: a retrospective analysis of 28 years’ experience at a single centre. Transplant Proc. 1997;29:823–30.
  28. Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161(Suppl 3):78–84.
  29. Vasudev B, Hariharan S. Cancer after renal transplantation. Curr Opin Nephrol Hypertens. 2007;16(6):523–8.
  30. Hofbauer GF, Anliker M, Arnold A, Binet I, Hunger R, Kempf W, et al.; SGDV working group for organ transplant recipients. Swiss clinical practice guidelines for skin cancer in organ transplant recipients. Swiss Med Wkly. 2009;139(29-30):407–15.